 <h1>Abrilada Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>adalimumab</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about adalimumab. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Abrilada.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to adalimumab: subcutaneous solution</i></p><h3>Warning</h3><p class="blackboxWarning-title">Subcutaneous route (Solution)</p><p>Patients treated with adalimumab are at increased risk of infection, some of which may become serious and lead to hospitalization or death. These infections have included TB, invasive fungal infections, bacterial, viral, and those caused by opportunistic pathogens including Legionella and Listeria. The risks and benefits of therapy should be carefully considered prior to treatment initiation in patients with chronic or recurrent infection. Evaluate for latent TB and treat if necessary prior to initiating therapy. Monitor patients closely for signs and symptoms of infection during and after treatment, including the possible development of TB in patients who tested negative prior to treatment. Consider empirical antifungal therapy in at-risk patients who develop severe systemic illness. Lymphoma and other malignancies, some fatal, have been reported in pediatric and adolescent patients treated with tumor necrosis factor (TNF) blockers such as adalimumab. Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), usually fatal, have been reported in patients treated with TNF blockers including adalimumab, primarily in adolescent and young adult males with Crohn disease and ulcerative colitis. Most cases occurred in patients receiving concomitant treatment with azathioprine or 6-mercaptopurine.</p><p class="blackboxWarning-title">Subcutaneous route (Solution)</p><p>Serious InfectionsIncreased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens.Discontinue adalimumab-bwwd if a patient develops a serious infection or sepsis during treatment.Perform test for latent TB; if positive, start treatment for TB prior to starting adalimumab-bwwd.Monitor all patients for active TB during treatment, even if initial latent TB test is negative.MalignancyLymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF-blockers including adalimumab products.Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have occurred in adolescent and young adults with inflammatory bowel disease treated with TNF-blockers including adalimumab products.</p><p class="blackboxWarning-title">Subcutaneous route (Solution)</p><p>Patients treated with adalimumab-atto are at increased risk of infection, some of which may become serious and lead to hospitalization or death. These infections have included TB, invasive fungal infections, bacterial, viral, and those caused by opportunistic pathogens including Legionella and Listeria. The risks and benefits of therapy should be carefully considered prior to treatment initiation in patients with chronic or recurrent infection. Evaluate for latent TB and treat if necessary prior to initiating therapy. Monitor patients closely for signs and symptoms of infection during and after treatment, including the possible development of TB in patients who tested negative prior to treatment. Consider empirical antifungal therapy in at-risk patients who develop severe systemic illness. Lymphoma and other malignancies, some fatal, have been reported in pediatric and adolescent patients treated with tumor necrosis factor (TNF) blockers, including adalimumab products. Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), usually fatal, have been reported in patients treated with TNF blockers including adalimumab products, primarily in adolescent and young adult males with Crohn disease and ulcerative colitis. Most cases occurred in patients receiving concomitant treatment with azathioprine or 6-mercaptopurine.</p><p class="blackboxWarning-title">Subcutaneous route (Solution)</p><p>Serious InfectionsIncreased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens.Discontinue adalimumab-adaz if a patient develops a serious infection or sepsis during treatment.Perform test for latent TB; if positive, start treatment for TB prior to starting adalimumab-adaz.Monitor all patients for active TB during treatment, even if initial latent TB test is negative.MalignancyLymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF-blockers including adalimumab products.Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have occurred in adolescent and young adults with inflammatory bowel disease treated with TNF-blockers including adalimumab products.</p><p class="blackboxWarning-title">Subcutaneous route (Solution)</p><p>Serious InfectionsIncreased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens.Discontinue adalimumab-afzb if a patient develops a serious infection or sepsis during treatment.Perform test for latent TB; if positive, start treatment for TB prior to starting adalimumab-afzb.Monitor all patients for active TB during treatment, even if initial latent TB test is negative.MalignancyLymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF-blockers including adalimumab products.Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have occurred in adolescent and young adults with inflammatory bowel disease treated with TNF-blockers including adalimumab products.</p><p class="blackboxWarning-title">Subcutaneous route (Solution)</p><p>Patients treated with adalimumab-adbm are at increased risk of infection, some of which may become serious and lead to hospitalization or death. These infections have included TB, invasive fungal infections, bacterial, viral, and those caused by opportunistic pathogens including Legionella and Listeria. The risks and benefits of therapy should be carefully considered prior to treatment initiation in patients with chronic or recurrent infection. Evaluate for latent TB and treat if necessary prior to initiating therapy. Monitor patients closely for signs and symptoms of infection during and after treatment, including the possible development of TB in patients who tested negative prior to treatment. Consider empirical antifungal therapy in at-risk patients who develop severe systemic illness. Lymphoma and other malignancies, some fatal, have been reported in pediatric and adolescent patients treated with tumor necrosis factor (TNF) blockers such as adalimumab-adbm. Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), usually fatal, have been reported in patients treated with TNF blockers including adalimumab-adbm, primarily in adolescent and young adult males with Crohn disease and ulcerative colitis. Most cases occurred in patients receiving concomitant treatment with azathioprine or 6-mercaptopurine.</p><p class="blackboxWarning-title">Subcutaneous route (Solution)</p><p>Serious InfectionsIncreased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens.Discontinue adalimumab-fkjp if a patient develops a serious infection or sepsis during treatment.Perform test for latent TB; if positive, start treatment for TB prior to starting adalimumab-fkjp.Monitor all patients for active TB during treatment, even if initial latent TB test is negative.MalignancyLymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF-blockers including adalimumab products.Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have occurred in adolescent and young adults with inflammatory bowel disease treated with TNF-blockers including adalimumab products.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, adalimumab (the active ingredient contained in Abrilada) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking adalimumab:</p><p>
<i>More common</i>
</p><ul>
<li>Body aches or pain</li>
<li>cough</li>
<li>ear congestion</li>
<li>gas with abdominal or stomach pain</li>
<li>hoarseness</li>
<li>lightheadedness</li>
<li>loss of voice</li>
<li>lower back or side pain</li>
<li>muscle aches and pains</li>
<li>nasal congestion</li>
<li>pain or tenderness around the eyes or cheekbones</li>
<li>rapid and sometimes shallow breathing</li>
<li>shivering</li>
<li>stomach fullness</li>
<li>sunken eyes</li>
<li>thirst</li>
<li>trouble sleeping</li>
<li>warmth on the skin</li>
<li>wrinkled skin</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Abnormal vaginal bleeding or discharge</li>
<li>agitation</li>
<li>arm, back, or jaw pain</li>
<li>black, tarry stools</li>
<li>bleeding from the gums or nose</li>
<li>blindness</li>
<li>bloating or swelling of the face, arms, hands, lower legs, or feet</li>
<li>blood in the stool or change in bowel habits</li>
<li>bloody or cloudy urine</li>
<li>blurred vision</li>
<li>broken bones</li>
<li>change in size, shape, or color of an existing mole</li>
<li>change in skin color</li>
<li>chest pain, tightness, or heaviness</li>
<li>chills</li>
<li>clear or bloody discharge from the nipple</li>
<li>cold hands and feet</li>
<li>confusion</li>
<li>constipation</li>
<li>cough</li>
<li>coughing or spitting up blood</li>
<li>decreased urination</li>
<li>decreased vision</li>
<li>depression</li>
<li>difficulty with breathing</li>
<li>difficulty, burning, or painful urination</li>
<li>dimpling of the breast skin</li>
<li>dizziness</li>
<li>drowsiness</li>
<li>eye pain</li>
<li>fainting</li>
<li>fast, slow, or irregular heartbeat</li>
<li>fever</li>
<li>forgetfulness</li>
<li>frequent urge to urinate</li>
<li>general feeling of illness</li>
<li>hair loss</li>
<li>headache</li>
<li>hives, itching, skin rash</li>
<li>increased thirst</li>
<li>inverted nipple</li>
<li>irregular breathing</li>
<li>irregular pulse</li>
<li>irritability</li>
<li>light colored stools</li>
<li>loss of appetite</li>
<li>lump in the breast or under your arm</li>
<li>lump or swelling in the abdomen or stomach</li>
<li>mole that leaks fluid or bleeds</li>
<li>muscle cramps or spasms</li>
<li>nausea</li>
<li>new mole</li>
<li>night sweats</li>
<li>no blood pressure or pulse</li>
<li>noisy breathing</li>
<li>numbness or tingling in your arms, legs, or face</li>
<li>pain, redness, or swelling in the arms or legs without any injury present</li>
<li>pale skin</li>
<li>persistent non-healing sore on your skin</li>
<li>pink growth</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>raised, firm, or bright red patch</li>
<li>redness or swelling of the breast</li>
<li>seeing or hearing things that are not there</li>
<li>seizures</li>
<li>sharp back pain just below your ribs</li>
<li>shiny bump on your skin</li>
<li>slurred speech or problems with swallowing</li>
<li>sneezing</li>
<li>sore on the skin of the breast that does not heal</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots on the lips or mouth</li>
<li>spitting up blood</li>
<li>stiff neck</li>
<li>stomach pain</li>
<li>stopping of the heart</li>
<li>sudden high fever or low grade fever for months</li>
<li>sweating</li>
<li>swelling of the face, fingers, feet, or lower legs</li>
<li>swollen glands</li>
<li>swollen neck veins</li>
<li>tiredness</li>
<li>troubled breathing with activity</li>
<li>trouble thinking</li>
<li>unconsciousness</li>
<li>unexplained bruising or bleeding</li>
<li>unpleasant breath odor</li>
<li>unusual tiredness or weakness</li>
<li>unusual weight gain or loss</li>
<li>visual disturbances</li>
<li>vomiting</li>
<li>vomiting of blood or material that looks like coffee grounds</li>
<li>yellow skin or eyes</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Blistering, peeling, or loosening of the skin</li>
<li>diarrhea</li>
<li>joint or muscle pain</li>
<li>pinpoint red spots on the skin</li>
<li>red skin lesions, often with a purple center</li>
<li>red, irritated eyes</li>
<li>red, scaling, or crusted skin</li>
<li>unusual bleeding or bruising</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of adalimumab may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Bladder pain</li>
<li>bleeding, blistering, burning, coldness, discoloration of skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site</li>
<li>pounding in the ears</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Abnormal healing</li>
<li>decrease in height</li>
<li>difficulty with moving</li>
<li>difficulty with walking</li>
<li>dry mouth</li>
<li>heartburn</li>
<li>indigestion</li>
<li>loss of hearing</li>
<li>loss of strength or energy</li>
<li>menstrual changes</li>
<li>muscle or joint stiffness, tightness, or rigidity</li>
<li>muscle pain or weakness</li>
<li>pain in the back, ribs, arms, or legs</li>
<li>shakiness in the legs, arms, hands, and feet</li>
<li>swelling or redness in the joints</li>
</ul><p>
<!-- end subcutaneous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to adalimumab: subcutaneous kit, subcutaneous solution</i></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Hypertension</p>
<p><b>Uncommon</b> (0.1% to 1%): Arrhythmia, atrial fibrillation, chest pain, coronary artery disorder, heart arrest, hypertensive encephalopathy, myocardial infarct, palpitation, pericardial effusion, pericarditis, syncope, tachycardia, congestive heart failure, peripheral edema, systemic vasculitis, deep vein thrombosis</p>
<p><b>Rare</b> (less than 0.1%): Vascular occlusion, aortic stenosis, thrombophlebitis, aortic aneurysm<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (12%)</p>
<p><b>Common</b> (1% to 10%): Dermatitis, eczema, pruritus, cellulitis, urticaria, psoriasis, ecchymosis, increased bruising, purpura, erysipelas, cutaneous vasculitis, herpes zoster</p>
<p><b>Postmarketing reports</b>: Stevens Johnson Syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis (all subtypes including pustular and palmoplantar), alopecia, erythema multiforme, panniculitis<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Uncommon</b> (0.1% to 1%): Parathyroid disorder<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Diarrhea, nausea, abdominal pain, vomiting, stomatitis, mouth ulceration</p>
<p><b>Uncommon</b> (0.1% to 1%): Cholecystitis, cholelithiasis, gastroenteritis, gastrointestinal hemorrhage, gastritis, dyspepsia, gastrointestinal disorder, gastrointestinal hemorrhage, rectal hemorrhage, abdominal bloating</p>
<p><b>Rare</b> (less than 0.1%): Esophagitis, intestinal stenosis, colitis, enteritis</p>
<p><b>Frequency not reported</b>: Diverticulitis, large bowel perforations including perforations associated with diverticulitis and appendiceal perforations associated with appendicitis, pancreatitis<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary tract infection, hematuria</p>
<p><b>Uncommon</b> (0.1% to 1%): Cystitis, kidney calculus, menstrual disorder, pyelonephritis<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Lymphopenia, agranulocytosis, granulocytopenia, leucopenia, thrombocytopenia, anemia, lymphadenopathy, leukocytosis </p>
<p><b>Rare</b> (less than 0.1%): Pancytopenia, polycythemia, idiopathic thrombocytopenia purpura, lymphoma-like reaction, leg thrombosis, hypertriglyceridemia<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Uncommon</b> (0.1% to 1%): Liver failure, hepatitis</p>
<p><b>Rare</b> (less than 0.1%): Hepatic enzymes increased, hepatic necrosis</p>
<p><b>Postmarketing reports</b>: Hepatic failure<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Anaphylaxis, angioneurotic edema<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Flu syndrome</p>
<p><b>Uncommon</b> (0.1% to 1%): Sarcoidosis</p>
<p><b>Frequency not reported</b>: Development of autoantibodies<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Injection site pain (12%)</p>
<p><b>Common</b> (1% to 10%): Injection site reaction<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Hypercholesterolemia, hyperlipidemia</p>
<p><b>Uncommon</b> (0.1% to 1%): Dehydration, ketosis, paraproteinemia, increased alkaline phosphatase<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Back pain</p>
<p><b>Uncommon</b> (0.1% to 1%): Arthritis, bone disorder, bone fracture (not spontaneous), bone necrosis, joint disorder, muscle cramps, myasthenia, pyogenic arthritis, synovitis, tendon disorder, pelvic pain</p>
<p><b>Rare</b> (less than 0.1%): Rhabdomyolysis<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (12%)</p>
<p><b>Uncommon</b> (0.1% to 1%): Confusion, paraesthesia, subdural hematoma, tremor, demyelinating disorders (e.g., optic neuritis, Guillain-Barre syndrome), cerebrovascular accident, multiple sclerosis, </p>
<p><b>Very rare</b> (less than 0.01%): Hypertrophic pachymeningitis<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Uncommon</b> (0.1% to 1%): Optic neuritis, cataract<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Uncommon</b> (0.1% to 1%): Adenoma, Merkel Cell Carcinoma (neuroendocrine carcinoma of the skin)</p>
<p><b>Rare</b> (less than 0.1%): Skin papilloma, carcinomas (breast, gastrointestinal, skin, testicular), lymphoma, melanoma, cancer of the white blood cells (known as Hepatosplenic T-Cell Lymphoma or HSTCL), mostly in adolescents and young adults<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Accidental injury (10%) </p>
<p><b>Uncommon</b> (0.1% to 1%): Pain in extremity, thorax pain</p>
<p><b>Rare</b> (less than 0.1%): Pyrexia</p>
<p><b>Frequency not reported</b>: Sepsis, pain in thorax, opportunistic infections, tuberculosis, histoplasmosis, abscess, joint infection, wound infection, superficial fungal infections<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Frequency not reported</b>: Renal pain, renal impairment<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Upper respiratory infection (17%), sinusitis (11%), pneumonia, pharyngitis, nasopharyngitis</p>
<p><b>Uncommon</b> (0.1% to 1%): Asthma, bronchospasm, dyspnea, lung function decreased, pleural effusion, interstitial lung disease (including pulmonary fibrosis), pulmonary embolism</p>
<p><b>Frequency not reported</b>: Cough, upper respiratory infection, pharyngeal edema, nasal congestion, pulmonary edema, pleural effusion, pleurisy<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Mood alterations (including depression), anxiety, insomnia<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. "Product Information. Humira (adalimumab)." Abbott Pharmaceutical, Abbott Park, IL. </p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>What are the new drugs for the treatment of rheumatoid arthritis (RA)?</li>
<li>What are the new drugs for the treatment of plaque psoriasis?</li>
<li>Can you take Humira with antibiotics?</li>
<li>How many biosimilars have been approved in the United States?</li>
<li>What is the difference between Amjevita and Humira?</li>
<li>What is the difference between Cyltezo and Humira?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Abrilada (adalimumab)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Drug class: TNF alfa inhibitors</li>
<li>FDA Alerts (4)</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Advanced Reading</li>
<li>ABRILADA Subcutaneous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Humira, Hadlima, Hulio, Cyltezo, ... +2 more</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Ankylosing Spondylitis</li>
<li>Crohn's Disease</li>
<li>Crohn's Disease, Acute</li>
<li>Crohn's Disease, Maintenance</li>
<li data-more-config-id="list-data-resources-conditions">... +6 more</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to adalimumab: subcutaneous kit, subcutaneous solution</i></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Hypertension</p><p><b>Uncommon</b> (0.1% to 1%): Arrhythmia, atrial fibrillation, chest pain, coronary artery disorder, heart arrest, hypertensive encephalopathy, myocardial infarct, palpitation, pericardial effusion, pericarditis, syncope, tachycardia, congestive heart failure, peripheral edema, systemic vasculitis, deep vein thrombosis</p><p><b>Rare</b> (less than 0.1%): Vascular occlusion, aortic stenosis, thrombophlebitis, aortic aneurysm<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (12%)</p><p><b>Common</b> (1% to 10%): Dermatitis, eczema, pruritus, cellulitis, urticaria, psoriasis, ecchymosis, increased bruising, purpura, erysipelas, cutaneous vasculitis, herpes zoster</p><p><b>Postmarketing reports</b>: Stevens Johnson Syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis (all subtypes including pustular and palmoplantar), alopecia, erythema multiforme, panniculitis<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Uncommon</b> (0.1% to 1%): Parathyroid disorder<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Diarrhea, nausea, abdominal pain, vomiting, stomatitis, mouth ulceration</p><p><b>Uncommon</b> (0.1% to 1%): Cholecystitis, cholelithiasis, gastroenteritis, gastrointestinal hemorrhage, gastritis, dyspepsia, gastrointestinal disorder, gastrointestinal hemorrhage, rectal hemorrhage, abdominal bloating</p><p><b>Rare</b> (less than 0.1%): Esophagitis, intestinal stenosis, colitis, enteritis</p><p><b>Frequency not reported</b>: Diverticulitis, large bowel perforations including perforations associated with diverticulitis and appendiceal perforations associated with appendicitis, pancreatitis<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary tract infection, hematuria</p><p><b>Uncommon</b> (0.1% to 1%): Cystitis, kidney calculus, menstrual disorder, pyelonephritis<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Lymphopenia, agranulocytosis, granulocytopenia, leucopenia, thrombocytopenia, anemia, lymphadenopathy, leukocytosis </p><p><b>Rare</b> (less than 0.1%): Pancytopenia, polycythemia, idiopathic thrombocytopenia purpura, lymphoma-like reaction, leg thrombosis, hypertriglyceridemia<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Uncommon</b> (0.1% to 1%): Liver failure, hepatitis</p><p><b>Rare</b> (less than 0.1%): Hepatic enzymes increased, hepatic necrosis</p><p><b>Postmarketing reports</b>: Hepatic failure<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Anaphylaxis, angioneurotic edema<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Flu syndrome</p><p><b>Uncommon</b> (0.1% to 1%): Sarcoidosis</p><p><b>Frequency not reported</b>: Development of autoantibodies<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Injection site pain (12%)</p><p><b>Common</b> (1% to 10%): Injection site reaction<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Hypercholesterolemia, hyperlipidemia</p><p><b>Uncommon</b> (0.1% to 1%): Dehydration, ketosis, paraproteinemia, increased alkaline phosphatase<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Back pain</p><p><b>Uncommon</b> (0.1% to 1%): Arthritis, bone disorder, bone fracture (not spontaneous), bone necrosis, joint disorder, muscle cramps, myasthenia, pyogenic arthritis, synovitis, tendon disorder, pelvic pain</p><p><b>Rare</b> (less than 0.1%): Rhabdomyolysis<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (12%)</p><p><b>Uncommon</b> (0.1% to 1%): Confusion, paraesthesia, subdural hematoma, tremor, demyelinating disorders (e.g., optic neuritis, Guillain-Barre syndrome), cerebrovascular accident, multiple sclerosis, </p><p><b>Very rare</b> (less than 0.01%): Hypertrophic pachymeningitis<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Uncommon</b> (0.1% to 1%): Optic neuritis, cataract<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Uncommon</b> (0.1% to 1%): Adenoma, Merkel Cell Carcinoma (neuroendocrine carcinoma of the skin)</p><p><b>Rare</b> (less than 0.1%): Skin papilloma, carcinomas (breast, gastrointestinal, skin, testicular), lymphoma, melanoma, cancer of the white blood cells (known as Hepatosplenic T-Cell Lymphoma or HSTCL), mostly in adolescents and young adults<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Accidental injury (10%) </p><p><b>Uncommon</b> (0.1% to 1%): Pain in extremity, thorax pain</p><p><b>Rare</b> (less than 0.1%): Pyrexia</p><p><b>Frequency not reported</b>: Sepsis, pain in thorax, opportunistic infections, tuberculosis, histoplasmosis, abscess, joint infection, wound infection, superficial fungal infections<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Frequency not reported</b>: Renal pain, renal impairment<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Upper respiratory infection (17%), sinusitis (11%), pneumonia, pharyngitis, nasopharyngitis</p><p><b>Uncommon</b> (0.1% to 1%): Asthma, bronchospasm, dyspnea, lung function decreased, pleural effusion, interstitial lung disease (including pulmonary fibrosis), pulmonary embolism</p><p><b>Frequency not reported</b>: Cough, upper respiratory infection, pharyngeal edema, nasal congestion, pulmonary edema, pleural effusion, pleurisy<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Mood alterations (including depression), anxiety, insomnia<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. "Product Information. Humira (adalimumab)." Abbott Pharmaceutical, Abbott Park, IL. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What are the new drugs for the treatment of rheumatoid arthritis (RA)?</li>
<li>What are the new drugs for the treatment of plaque psoriasis?</li>
<li>Can you take Humira with antibiotics?</li>
<li>How many biosimilars have been approved in the United States?</li>
<li>What is the difference between Amjevita and Humira?</li>
<li>What is the difference between Cyltezo and Humira?</li>
</ul><h2>More about Abrilada (adalimumab)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Drug class: TNF alfa inhibitors</li>
<li>FDA Alerts (4)</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Advanced Reading</li>
<li>ABRILADA Subcutaneous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Ankylosing Spondylitis</li>
<li>Crohn's Disease</li>
<li>Crohn's Disease, Acute</li>
<li>Crohn's Disease, Maintenance</li>
<li data-more-config-id="list-data-resources-conditions">... +6 more</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>